On May 27, 2022, OliX Pharmaceuticals, Inc closed the transaction. The company issued 2,210,527 registered convertible preferred shares for gross proceeds of KRW 57,000,000,000 in the transaction. The transaction included participation from new investors KB Investment, IMM Investment Corp, Company K Partners, Solidus Investment Co Ltd, Susung Asset Management Co Ltd, Welcome Asset Management, Focus Asset Management, and Shinhan Capital participated in this third-party capital increase.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7,040 KRW | +1.15% | +1.88% | +5.55% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+5.55% | 80.54M | |
+14.52% | 3.1B | |
+31.41% | 2.06B | |
+8.00% | 1.51B | |
-11.54% | 1.19B | |
+14.37% | 726M | |
+9.28% | 674M | |
+33.12% | 556M | |
-4.17% | 500M | |
+25.78% | 462M |
- Stock Market
- Equities
- A307930 Stock
- News Company K Partners Limited
- OliX Pharmaceuticals, Inc announced that it has received KRW 57 billion in funding from a group of investors